The German molecular diagnostics company, Curetis AG, has raised €12.5 million in a Series B round to further test and commercialise its technology for detecting antibiotic resistant bacteria. The round was led by HBM Partners of Switzerland. ---Subscribe to MedNous to access this article--- Finance, Grants, Deals Company News
